Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine
Vaccination
About this trial
This is an interventional prevention trial for Vaccination
Eligibility Criteria
Inclusion Criteria:
- subjects aged from 18 to 24 months old at the date of recruitment;
- with informed consent signed by parent(s) or guardians;
- parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions;
- subjects have not been vaccinated with any type of Hepatitis A vaccines;
- subjects have no Hepatitis A disease and contraindication of vaccination;
- subjects did not receive any vaccines within 14 days;
- before joining this trial, subjects must be qualified and passed their medical history and clinical examinations, and axillary's temperature must be ≤37℃.
Exclusion Criteria:
- Subjects with history of allergy, convulsion, epilepsy, encephalopathy and psychosis or family history;
- Allergic to any ingredient of vaccine or with allergy history to any vaccine;
- Patients with immunodeficiency, in process of cancer treatment, immunosuppressive therapy (oral steroids) or HIV induced hypoimmunity, or in close contact with any family members who has congenital immune diseases;
- Receive non-specific immunoglobulin within 1 month before recruitment;
- Subjects with acute febrile diseases with body temperature > 37.0 ℃ or infectious diseases;
- Subjects with a history of thrombocytopenia or other coagulation disorders that may be contraindicated for hypodermic injection;
- With known or suspected concurrent diseases include respiratory disease, acute infection or active chronic disease;
- With severe cardiovascular diseases (Pulmonary heart disease, Pulmonary edema, hypertension cannot be controlled to normal range by drugs), liver and kidney diseases and diabetic complications;
- Various infectious, suppurative or allergic dermatitis;
- Other circumstances judged by investigators that are not suitable for this clinical trial.
Sites / Locations
- Yangxian Center for Disease Control and Prevention
- Mianxian Center for Disease Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
Research Group 1
Research Group 2
Research Group 3
150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.